Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B

Table 5 Significant predictors of overall treatment success, mycological response and mortality

Variable	Ratio	Without interaction terms^a	With interaction terms
			Maximum likelihood estimate (± standard error)	Wald χ² (probability > χ²)
Overall treatment success
ICU status^b	Not in ICU to in ICU	1.866 (1.147 to 3.034)	0.1380 ± 0.5438	0.0644 (0.7997)
Persistent neutropenia	Non-neutropenic to neutropenic	5.721 (1.412 to 23.169)	1.7185 ± 0.7156	5.7669 (0.0163)
APACHE II score	High to low (continuous)	0.956 (0.929 to 0.983)	--0.0468 ± 0.0144	10.6416 (0.011)
Mycological response
ICU status^b	Not in ICU to in ICU	1.778 (1.037 to 3.048)	--0.0223 ± 1.7567	0.0002 (0.9899)
Primary diagnosis	Candidemia to invasive candidiasis	2.465 (1.343 to 4.524)	0.3246 ± 0.4368	0.5522 (0.4574)
Neutropenia^b	Non-neutropenic to neutropenic	2.357 (1.134 to 4.898)	--0.9093 ± 1.0206	3.4859 (0.0619)
Diabetes mellitus	No to yes	0.350 (0.137 to 0.894)	--1.0113 ± 0.5362	3.5572 (0.0593)
APACHE II score	High to low (continuous)	0.953 (0.925 to 0.982)	--0.0505 ± 0.0154	10.7417 (0.001)
All-cause mortality at day 8
Candida spp.	Candida krusei to other Candida spp.	3.536 (1.039 to 12.035)	2.4861 ± 1.3739	3.2745 (0.0704)
APACHE II score	High to low (continuous)	1.097 (1.055 to 1.142)	0.0931 ± 0.0208	20.0498 (< 0.0001)
All-cause mortality at day 30
Age	Low to high	1.018 (1.003 to 1.033)	0.0170 ± 0.0076	4.9331 (0.0263)
Persistent neutropenia	Non-neutropenic to neutropenic	0.160 (0.039 to 0.658)	--1.7845 ± 0.7146	6.2358 (0.0125)
APACHE II score	High to low (continuous)	1.093 (1.057 to 1.131)	0.0937 ± 0.0178	27.7797 (< 0.0001)

Significant predictors of overall treatment success, mycological response and mortality based on a logistic regression model that controlled for potential confounding variables with and without interaction terms. APACHE, Acute Physiology and Chronic Health Evaluation; ICU, intensive care unit. ^aOdds ratio (95% confidence interval). ^bAt the time of treatment initiation.

ISSN: 1364-8535